Immune checkpoint inhibitors have been shown to be effective regardless of BRAF mutation status. Subgroup analyses in CheckMate 067 and 069 have demonstrated improved efficacy with nivolumab-ipilimumab combination therapy compared with ipilimumab monotherapy, irrespective of BRAF mutation status, noted by both the NCCN and EDF guidelines.
BRAF inhibitors combined with MEK inhibitors have been shown to be superior to BRAF inhibitor monotherapy, both in terms of progression-free survival and overall survival, whereas toxicity is similar and controllable between the two.
Learn more about the treatment of metastatic melanoma.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Adil Daud. Fast Five Quiz: Metastatic Melanoma - Medscape - Mar 15, 2023.